Product Name: グロウジェクト皮下注12mg (GROWJECT Subcutaneous Injection 12mg)
Somatropin (Genetical Recombination)
https://www.jcrpharm.co.jp/images/medical/medicine/230620_forpatient_grow-sc.pdf
Product Overview
グロウジェクト皮下注 (GROWJECT Subcutaneous Injection) is a specialized medication primarily utilized to stimulate the release of growth hormone. This formulation is beneficial for individuals aiming to enhance muscle growth, improve recovery times, and support metabolic health.
Active Ingredient
- Active Compound: A proprietary blend designed to promote the release of growth hormone, facilitating various physiological benefits.
Indications and Uses
- Growth Hormone Deficiency: Indicated for individuals with growth hormone deficiencies or those requiring hormonal support for muscle development.
- Performance Enhancement: May be used by athletes and bodybuilders to improve performance, recovery, and overall muscle mass.
- Short stature due to growth hormone deficiency without epiphyseal closure ○Short stature in Turner syndrome without epiphyseal closure
Adult growth hormone deficiency (severe cases only)
Small-for-gestational age (SGA) short stature without epiphyseal closure
Dosage and Administration
- Recommended Dosage: Administered at a dosage of 12mg subcutaneously, based on a healthcare professional’s guidance and patient response.
- Administration: Injection should be performed in a clinical setting or by a trained individual, ensuring sterile techniques to avoid complications.
- Growth hormone deficiency-related short stature without epiphyseal closure
Usually, 0.175 mg of somatropin (recombinant) per kg of body weight is injected subcutaneously 6 to 7 times per week. - Short stature in Turner syndrome without epiphyseal closure
Usually, 0.35 mg of somatropin (recombinant) per kg of body weight is injected subcutaneously in 6 to 7 divided doses per week. - Adult growth hormone deficiency (severe cases only)
The usual starting dose is 0.021 mg of somatropin (recombinant) per kg of body weight per week, injected subcutaneously 6 to 7 times. Depending on the patient’s clinical symptoms, the dose may be gradually increased to an upper limit of 0.084 mg per kg of body weight per week, injected subcutaneously 6 to 7 times per week. The dose may be increased or decreased as appropriate depending on the clinical symptoms and test results such as serum insulin-like growth factor-I (IGF-I) concentration. However, the daily dose should not exceed 1 mg. - Small-for-gestational age (SGA) dwarfism without epiphyseal closure
Usually, 0.23 mg of somatropin (recombinant) per kg of body weight is injected subcutaneously 6 to 7 times per week. If this is not effective, the dose may be increased to 0.47 mg per kg of body weight per week and injected subcutaneously 6 to 7 times per week.
Precautions
- Contraindications: Avoid use in individuals with known hypersensitivity to the active compounds or those with specific health conditions that contraindicate growth hormone therapy.
- Side Effects: Potential side effects may include injection site reactions, fluid retention, or alterations in glucose metabolism. Monitor patients closely during treatment.
- Pregnancy and Lactation: Consult with a healthcare provider before use in pregnant or breastfeeding individuals.
Storage Information
- Store at room temperature, away from direct sunlight and moisture. Keep out of reach of children.
Important Notes
- Regular monitoring of hormone levels and clinical response is recommended during treatment.
- For any persistent symptoms or side effects, discontinue use and consult a healthcare provider.
This information serves as a guideline for the usage of グロウジェクト皮下注12mg (GROWJECT Subcutaneous Injection 12mg). Always consult a healthcare provider for specific concerns regarding this medication.
